DalsnaFinance › Analyst accuracy › Wells Fargo › AMGN target
Wells Fargo raises Amgen stock price target to $435 on drug trial outlook
Wells Fargo raises Amgen stock price target to $435 on drug trial outlook
A fact about what Wells Fargo published, as reported by Investing.com India, not a recommendation from Dalsna Finance; Wells Fargo is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.